USPTO Deadlines
Next Deadline
In Grace Period
Section 8 (6-Year) Declaration Due (Based on registration date 2019-04-30)
Due Date
April 30, 2025
Grace Period Ends
October 30, 2025
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
30 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 7, 2025 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Nov 28, 2024 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
| Apr 30, 2024 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | Loading... |
| May 28, 2020 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Sep 13, 2019 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Aug 24, 2019 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Aug 24, 2019 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Jul 30, 2019 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| May 13, 2019 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Apr 30, 2019 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Feb 12, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 12, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 8, 2019 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Jan 23, 2019 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Jan 23, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 23, 2019 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Dec 28, 2018 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 27, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 27, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 27, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Dec 27, 2018 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jul 14, 2018 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jun 28, 2018 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jun 28, 2018 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Jun 20, 2018 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Jun 19, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 12, 2018 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 5, 2018 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Jun 1, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 24, 2018 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for preventing and treating obesity; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for wounds; pharmaceutical preparations for activating cellular function; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of infectious diseases; Synthetic peptides for pharmaceutical purposes for treating hypertension; Synthetic peptides for pharmaceutical purposes for the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of hormonal disorders and the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of eye diseases and conditions; Synthetic peptides for pharmaceutical purposes for the treatment of multiple sclerosis; Synthetic peptides for pharmaceutical purposes for treating diabetes; Synthetic peptides for pharmaceutical purposes for affecting metabolism; Synthetic peptides for pharmaceutical purposes for regulating the immune system; Synthetic peptides for pharmaceutical purposes for the treatment of viral diseases; Synthetic peptides for pharmaceutical purposes for affecting and treating urogenital organs; Synthetic peptides for pharmaceutical purposes for preventing and treating obesity; Synthetic peptides for pharmaceutical purposes for the treatment of bone diseases; Synthetic peptides for pharmaceutical purposes for wounds; Synthetic peptides for pharmaceutical purposes for activating cellular function; Synthetic peptides for pharmaceutical purposes for affecting digestive organs; Synthetic peptides for pharmaceutical purposes for the treatment of cardiovascular disease; Synthetic peptides for pharmaceutical purposes for treating malignant tumours; Synthetic peptides for pharmaceutical purposes for the treatment and prevention of cancer; Synthetic peptides for pharmaceutical purposes for treatment of viral and infectious diseases, for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of auto-immune diseases
Additional Information
Design Mark
The mark consists of a stylized design consisting of two ovals connected by 5 lines to two more ovals that are divided, and are stacked above two other ovals. To the right of the stylized design are the letters "hyFc" stacked above the word "technology".
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"TECHNOLOGY"